.png){kind=icon}
返回
C
Chloe Orkin
Queen Mary University of London
63H指数
335论文数
1.7W被引数
收录论文 142
发表时间
.png){kind=icon}
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial在接受口服抗逆转录病毒治疗的HIV-1的病毒学抑制成人中，每天一次改用固定剂量的doravirine (100 mg) 和islatravir (0·25 mg): 3期，多中心，随机，开放标签，非劣效性试验的48周结果.png)
The Lancet.png)
The LancetIF97.3
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏Outcomes of real-world initiation of long-acting injectable cabotegravir and rilpivirine (LA-I CAB plus RPV) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations真实世界中长期作用注射用卡博格韦和 rilpivirine（LA-I CAB plus RPV）在伴有病毒血症个体中的启动结局：一项关于基线特征、病毒学失败结局和停药情况的系统综述HIV MEDICINE
OAAI
HIV MEDICINEIF3.2
OAAI分享收藏Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process建立长效注射用卡博格韦和 rilpivirine 治疗的病毒学失败和停药共享定义（CONSENSUS-LAI 研究）：一项国际调查和德尔菲过程lancet hivOAAI
lancet hivIF0
OAAI分享收藏Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV长效注射用卡博格韦和拉米夫定在观察性队列研究中的使用：关于病毒抑制的HIV感染者病毒学失败、耐药性及病毒再抑制结局的系统评价HIV MedicineOAAI
HIV MedicineIF3.2
OAAI分享收藏Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studiesBictegravir/emtricitabine/tenofovir alafenamide在启动一线治疗的HIV-1感染的黑人和西班牙裔/拉丁裔成人中的疗效与安全性：两项III期研究的5年随访结果HIV MEDICINEOAAI
HIV MEDICINEIF3.2
OAAI分享收藏